Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Asthika Goonewardene
TRU
Asthika Goonewardene
Truist Financial
Wall Street Analyst
★★★★☆
#410
on 13Foresight · ranked by our own returns
64%
Success Rate
+18.9%
Average Return
16 of 25 calls profitable · +8.9% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 64% of Asthika Goonewardene's ratings turned a profit when each position was held for 1 year — averaging +18.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

93 Buy 11 Hold 0 Sell
Asthika's Stock Coverage 23 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
AVBP
ArriVent BioPharma, Inc.
 May 29, 2026 BUY Strong Buy
+38.0% avg upside
15 analysts
$45.00
42.45% Upside
 +3.6%
ACET
Adicet Bio
 Mar 16, 2026 BUY Strong Buy
+212.2% avg upside
14 analysts
 — +13.8%
BNTX
BioNTech SE
 Mar 13, 2026 BUY Strong Buy
+48.8% avg upside
26 analysts
$155.00
71.19% Upside
 -0.4%
ALLO
Allogene Therapeutics
 Mar 13, 2026 BUY Strong Buy
+673.3% avg upside
28 analysts
$10.00
398.77% Upside
 -20.8%
LEGN
Legend Biotech
 Mar 13, 2026 BUY Strong Buy
+115.9% avg upside
27 analysts
$70.00
148.39% Upside
 +91.3%
CRBU
Caribou Biosciences
 Mar 09, 2026 BUY Strong Buy
+585.9% avg upside
12 analysts
$7.00
341.58% Upside
 +8.6%
RVMD
Revolution Medicines
 Mar 09, 2026 BUY Strong Buy
-10.2% avg upside
32 analysts
 — +58.1%
ZYME
Zymeworks
 Mar 03, 2026 BUY Strong Buy
+39.8% avg upside
25 analysts
$40.00
74.28% Upside
 -4.9%
CGEN
Compugen
 Mar 03, 2026 BUY Strong Buy
+172.6% avg upside
8 analysts
$4.00
100.08% Upside
 +51.5%
SEPN
Septerna, Inc.
 Mar 02, 2026 BUY Strong Buy
+19.4% avg upside
12 analysts
 — +6.2%
RCUS
Arcus Biosciences
 Feb 27, 2026 BUY Strong Buy
+39.2% avg upside
20 analysts
$30.00
24.69% Upside
 +18.6%
IOVA
Iovance Biotherapeutics
 Feb 25, 2026 HOLD Strong Buy
+223.6% avg upside
24 analysts
 — -9.9%
GMAB
Genmab
 Feb 25, 2026 BUY Buy
+38.1% avg upside
26 analysts
$48.00
90.21% Upside
 -9.4%
SMMT
Summit Therapeutics
 Feb 24, 2026 BUY Strong Buy
+109.1% avg upside
27 analysts
$35.00
154.45% Upside
 -14.0%
EXEL
Exelixis
 Jan 14, 2026 BUY Strong Buy
-21.4% avg upside
33 analysts
$51.00
2.16% Downside
 +17.5%
AUTL
Autolus Therapeutics
 Jan 13, 2026 BUY Strong Buy
+597.7% avg upside
16 analysts
$8.00
421.23% Upside
 +6.6%
STRO
Sutro Biopharma
 Nov 11, 2025 BUY Strong Buy
+37.1% avg upside
20 analysts
 — +255.6%
GILD
Gilead Sciences
 Nov 03, 2025 BUY Strong Buy
-5.6% avg upside
66 analysts
$145.00
18.06% Upside
 +3.3%
DGX
Quest Diagnostics
 Apr 24, 2024 HOLD Buy
-13.1% avg upside
33 analysts
 — +30.4%
TIL
Instil Bio
 Mar 21, 2024 HOLD Buy
+339.1% avg upside
8 analysts
 — +52.0%
CELU
Celularity
 Jan 16, 2024 HOLD Strong Buy
+1879.1% avg upside
6 analysts
 — +10.0%
NXTC
NextCure
 Aug 23, 2022 BUY Buy
+721.9% avg upside
10 analysts
$15.00
617.69% Upside
 -64.9%
GB:0MGB
Genmab A/S
 Jul 14, 2022 BUY Buy
+34.6% avg upside
22 analysts
$341.11
78.84% Downside
 ·
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Asthika Goonewardene — Frequently Asked Questions
How accurate are Asthika Goonewardene's stock ratings?
Based on the calls 13Foresight could measure, about 64% of Asthika's ratings were profitable over a one-year hold, with an average return of +18.9% per rating, or +8.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Asthika ranked on 13Foresight?
Asthika Goonewardene is currently ranked #410 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Asthika cover?
Asthika most recently has ratings on AVBP, ACET, BNTX, ALLO, LEGN, CRBU, RVMD, ZYME, CGEN, SEPN, RCUS, IOVA and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.